Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to $212.9 million.

  • Janux Therapeutics' Change in Acquisitions & Divestments rose 179.79% to $126.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.4 million, marking a year-over-year increase of 55.44%. This contributed to the annual value of $212.9 million for FY2024, which is 23.41% down from last year.
  • Janux Therapeutics' Change in Acquisitions & Divestments amounted to $212.9 million in FY2024, which was down 23.41% from $278.0 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Change in Acquisitions & Divestments peaked at $359.1 million during FY2022, and registered a low of $134.1 million during FY2021.
  • Over the past 3 years, Janux Therapeutics' median Change in Acquisitions & Divestments value was $278.0 million (recorded in 2023), while the average stood at $283.3 million.
  • As far as peak fluctuations go, Janux Therapeutics' Change in Acquisitions & Divestments surged by 167.70% in 2022, and later fell by 23.41% in 2024.
  • Yearly analysis of 4 years shows Janux Therapeutics' Change in Acquisitions & Divestments stood at $134.1 million in 2021, then surged by 167.70% to $359.1 million in 2022, then declined by 22.58% to $278.0 million in 2023, then decreased by 23.41% to $212.9 million in 2024.